Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications
Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.
Journal: Leukemia & lymphoma
Published: June 25, 2026
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: May 06, 2026
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors.
Journal: Cancer discovery
Published: February 05, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.
Journal: Current medical research and opinion
Published: January 30, 2026
Can minimal residual disease be used to tailor therapy duration for chronic lymphocytic leukemia patients?
Journal: Expert review of hematology
Published: January 18, 2026
Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience.
Journal: Blood cancer journal
Published: October 03, 2025
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026.
Journal: Mayo Clinic proceedings
Published: September 09, 2025
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 29, 2025
Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia.
Journal: HemaSphere
Published: June 27, 2025
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 27, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 06, 2025
Last Updated: 09/26/2026